British biotech generally raised more across public and private markets in Q3 2026, despite an overall downturn in the flow of VC more generally into the UK.

Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing the tumour microenvironment across immuno-oncology programmes ...

GSK's likely blockbuster-to-be led to a fifth of patients having undetectable viral levels in clinical trials.

AI Proteins and Astellas Innovation Management have signed a research collaboration and licence deal to discover and develop miniprotein therapeutics.

With the AI revolution underway, sustainability is now a key consideration for pharma companies building and utilising data centres.

Celltrion has acquired exclusive global development and commercialisation rights to Kaigene's investigational monoclonal antibody, KG013, in a deal worth up to $580m.

Numerous types of equity deals involving Chinese biotech, including the popular NewCo model, will be impacted by the proposed rule.

Boehringer Ingelheim and Microsoft have entered into a strategic collaboration to examine the use of AI in clinical research, beginning with studies in lung health.

This deal sees Gilead double down on TCEs, following its first bet on the modality through its buyout of autoimmune-focused Ouro Medicines.

The US Food and Drug Administration (FDA) has rolled out a new framework to spur development of new therapies for rare diseases, marking the latest initiative carried out by the T ...

Acta Pharmaceuticals has secured $24m in seed funding for advancing a drug pipeline focused on early intervention and prevention of AD, including the clinical progression of its lead candidate, ...

Following its provisional blessing in IgAN, AstraZeneca's Ultomiris is now indicated for use in six conditions.